Dana-Farber’s Breast Oncology Center
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Dana-Farber’s Breast Oncology Center
Feb 15, 2024, 18:29 |
Blog
,
Insight
The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X/Twitter: ''The MARGOT study led by Dana-Farber’s…
Feb 14, 2024, 13:13 |
Blog
Chiara Corti: Thanks so much to Gianni Bonadonna Foundation and AIRC Foundation for cancer research for this opportunity
Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post by Gianni Bonadonna Foundation…
Feb 7, 2024, 14:13 |
Blog
Sarah Sammons: When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable.
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter: "To…
Jan 29, 2024, 13:37 |
Blog
Sarah Sammons: Learning about Leptomeningeal Disease in Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber's Breast Oncology Center, shared a post on X/Twitter:…
Jan 26, 2024, 17:17 |
Societies
30 Posts Not To Miss From ASCO GI24
The ASCO Gastrointestinal Cancer Symposium (GI24) took place from the 18th to the 20th of…
Dec 11, 2023, 11:27 |
Insight
Margaret Gatti-Mays: A great option for our patients with TNBC
Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James…
Nov 27, 2023, 17:37 |
Blog
Congrats to rising star Alinés Lebrón-Torres - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X/Twitter: "Congrats to rising star Alinés Lebrón-Torres!…
1
2
3
4
All:
37
Posts:
31 - 40
Career Journey to President and CEO - OncoInfluencers
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Facebook
RSS Feed
Twitter
Linkedin
Youtube